January 2nd 2024
Overall, 39.1% of patients with malignant ureteral obstruction were referred to palliative care over the study period.
September 29th 2023
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
View More
New York GU 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
March 8-9, 2024
Register Now!
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Novel TKI/immunotherapy combo shows promise in advanced kidney cancer
April 22nd 2022Combination therapy with the novel TKI sitravatinib and the anti–PD-1 immune checkpoint inhibitor nivolumab showed promising efficacy and safety in patients with clear cell renal cell carcinoma and progression after antiangiogenic therapy.
Presentation, diagnosis, and management of a rare case of urachal adenocarcinoma
April 21st 2022"Urachal carcinoma is a rare and aggressive malignancy. The low incidence of the disease results in limited large-scale clinical trials that could provide standardized guidelines for its diagnosis and management," write Christopher Pieczonka, MD, and Peter Fioramonti, BS.
Rare diagnosis of penile cancer causes higher mortality rates and stigma, expert says
March 18th 2022Stigmas about the disease have negatively impacted the treatment and management of penile cancer, such that patients feel shamed for having the condition and do not seek care, and physicians may not have enough experience with the disease to appropriately provide care. Curtis A. Pettaway, MD, discusses these stigmas further in the following interview.
New society for rare genitourinary cancers aims to build education and awareness
January 21st 2022In a recent interview, Philippe E. Spiess, MD, and Andrea Necchi, MD, shared how they aim to develop an environment that emphasizes education, patient advocacy, and clinical research for rare genitourinary cancers.
Dr. Stewart assesses novel renal cancer treatment
October 14th 2021“Clearly, we are now in that era of TKIs in addition to checkpoint inhibitors, and so…it makes logical sense from the place we're at [in] the moment in renal cancer treatment with those combinations of treatment,” says Grant Stewart, MD.
Heart disease risk higher in GU cancer survivors
March 18th 2021“The good news is that we’re getting really good at treating cancer and we have more survivors, but we need to start thinking more carefully about the non-cancer risks following a diagnosis, one of which is cardiovascular disease,” said senior author Ashley Felix, PhD.
From Dr. Concepcion: Lessons learned in the COVID-19 pandemic
March 15th 2021"I hope many readers have taken the opportunity to learn from the evolving science and gone back to review the basics of virology, immune response, and clinical trial development to gain a better understanding of this global pathogen," writes Raoul S. Concepcion, MD, FACS.